Eli Lilly and (LLY) to Release Quarterly Earnings on Wednesday
Eli Lilly and (NYSE:LLY) is set to release its earnings data before the market opens on Wednesday, January 31st. Analysts expect Eli Lilly and to post earnings of $1.07 per share for the quarter.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter in the prior year, the firm earned $0.88 earnings per share. The firm’s revenue was up 9.0% compared to the same quarter last year. On average, analysts expect Eli Lilly and to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Shares of Eli Lilly and (NYSE LLY) opened at $84.42 on Wednesday. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and has a 12-month low of $74.00 and a 12-month high of $89.09. The stock has a market cap of $92,950.00, a price-to-earnings ratio of 40.20, a PEG ratio of 1.67 and a beta of 0.35.
Several brokerages have recently issued reports on LLY. Morgan Stanley set a $86.00 price objective on shares of Eli Lilly and and gave the stock a “hold” rating in a research report on Friday, October 6th. Leerink Swann increased their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, October 24th. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their price objective for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Finally, Goldman Sachs Group downgraded shares of Eli Lilly and from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $86.98 to $95.00 in a research report on Tuesday, January 16th. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $92.41.
In related news, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the transaction, the insider now owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the completion of the transaction, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 251,088 shares of company stock valued at $22,041,236. 0.20% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: “Eli Lilly and (LLY) to Release Quarterly Earnings on Wednesday” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://theolympiareport.com/2018/01/24/eli-lilly-and-lly-to-release-quarterly-earnings-on-wednesday.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.